Bruker Corporation
BRKRBruker Corporation (BRKR) is a global leader in scientific instrumentation and analytical solutions. It specializes in high-performance tools for molecular and materials research, including mass spectrometry, nuclear magnetic resonance (NMR), and other analytical techniques. The company's products are widely used in healthcare, pharmaceuticals, academia, and industrial research to support scientific discovery and quality control.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 2, 2026 | $0.05 | 2025-12-08 | 2025-12-08 |
| October 3, 2025 | $0.05 | 2025-09-23 | 2025-09-23 |
| June 27, 2025 | $0.05 | 2025-06-16 | 2025-06-16 |
| March 28, 2025 | $0.05 | 2025-03-17 | 2025-03-17 |
| December 16, 2024 | $0.05 | 2024-12-02 | 2024-12-02 |
Dividends Summary
- Consistent Payer: Bruker Corporation has rewarded shareholders with 40 dividend payments over the past 10 years.
- Total Returned Value: Investors who held BRKR shares during this period received a total of $1.76 per share in dividend income.
- Latest Payout: The most recent dividend of $0.05/share was paid 21 days ago, on January 2, 2026.
- Yield & Schedule: BRKR currently pays dividends quarterly with an annual yield of 0.38%.
- Dividend Growth: Since 2016, the dividend payout has grown by 25.0%, from $0.04 to $0.05.
- Dividend Reliability: BRKR has maintained or increased its dividend for 40 consecutive payments.
Company News
Markets traded cautiously on Tuesday despite benign inflation data (CPI at 2.7% YoY, core CPI at 2.6%) that supported Fed rate cut expectations. Silver surged 4.5% to $89/oz amid supply concerns. Major indices remained flat with the S&P 500 near record highs. Earnings results were mixed: JPMorgan fell 3% on weak investment banking fees, Delta sli...
Lane Generational, a Massachusetts-based investment advisor, completely sold its $3.6 million stake in Bruker during Q3 2025, exiting all 87,607 shares amid the company's challenging market performance.
The global molecular spectroscopy market is projected to grow from USD 6.97 billion in 2024 to USD 9.04 billion by 2034, driven by expanding healthcare applications, research growth, and technological advancements in drug discovery and diagnostics.
The next-generation proteomics market is projected to expand rapidly between 2025-2034, driven by technological advancements, rising chronic disease prevalence, and increasing demand for personalized medicine across pharmaceutical, biotechnology, and diagnostic sectors.
The global PFAS testing market is projected to grow from $306.60 million in 2024 to $1.25 billion by 2037, driven by increasing environmental and health regulations around 'forever chemicals' across North America, Europe, and Asia.
